A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.

@article{Fury2011AP2,
  title={A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.},
  author={Matthew G. Fury and S. M. S. Sirajul Haque and Hilda E. Stambuk and Ronglai Shen and Diane Carlson and David G. Pfister},
  journal={Cancer},
  year={2011},
  volume={117 4},
  pages={795-801}
}
BACKGROUND Preclinical studies suggest that additive or synergistic effects are achieved with the combination of pemetrexed plus gemcitabine. A phase 1 study of pemetrexed plus gemcitabine given every 2 weeks demonstrated encouraging preliminary efficacy against head and neck squamous cell cancer (HNSCC). METHODS This was an open-label, single-institution, single-arm, phase 2 study for patients who had received no more than 2 cytotoxic regimens for recurrent and/or metastatic HNSCC. All… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): updated results of a phase II trial—ASCO [abstract

  • TM Feinstein, LE Raez, KK Rajasenan
  • J Clin Oncol. 2008;26(May 20suppl). Abstract
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…